1. Imunohistokemična analiza izražanja glukokortikoidnih receptorjev pri zgodnjem raku dojk in njihov vpliv na odgovor na zdravljenje z neoadjuvantno sistemsko terapijoMarjetka Sraka, Barbara Gazić, Primož Drev, Cvetka Grašič-Kuhar, 2024, izvirni znanstveni članek Povzetek: Glukokortikoidni receptor (GR) je različno izražen na tumorskih in imunskih celicah raka dojk, njegova izraženost pa je morda odvisna od molekularnega podtipa raka dojk, prav tako njegova izraženost morda vpliva na odgovor na neoad-juvantno sistemsko terapijo. Naš namen je vpeljati zanesljivo imunohistokemično barvanje s protitelesi proti GR, drugi namen pa je oceniti izraženost GR na vzorcih raka dojk in preučiti, ali se ta izraža različno pri različnih podtipih in ali njegova izraženost vpliva na odgovor na neoadjuvantno sistemsko terapijo. Ključne besede: rak dojk, neoadjuvantno sistemsko zdravljenje, glukokortikoidni receptor Objavljeno v DiRROS: 26.07.2024; Ogledov: 16; Prenosov: 4
Celotno besedilo (7,50 MB) |
2. Association of OPRM1, MIR23B, and MIR107 genetic variability with acute pain, chronic pain and adverse effects after postoperative tramadol and paracetamol treatment in breast cancerZala Vidic, Katja Goričar, Branka Stražišar, Nikola Bešić, Vita Dolžan, 2023, izvirni znanstveni članek Povzetek: Background. Tramadol is an opioid analgesic often used for pain management after breast cancer surgery. Its anal-gesic activity is due to the activation of the μ-opioid receptor, encoded by the OPRM1 gene. This study investigated the association of genetic variability in OPRM1 and its regulatory miRNA genes with outcomes of tramadol/paraceta-mol treatment after breast cancer surgery with axillary lymphadenectomy.Patients and methods. The study included 113 breast cancer patients after breast cancer surgery with axillary lymphadenectomy treated with either 75/650 mg or 37.5/325 mg of tramadol with paracetamol for pain relief within the randomized clinical trial KCT 04/2015-DORETAonko/si at the Institute of Oncology Ljubljana. All patients were geno-typed for OPRM1 rs1799971 and rs677830, MIR23B rs1011784, and MIR107 rs2296616 using competitive allele-specific PCR. The association of genetic factors with acute and chronic pain as well as adverse effects of tramadol treatment was evaluated using logistic regression, Fisher’s exact test, and Mann-Whitney test.Results.The investigated OPRM1 related polymorphisms were not associated with acute pain assessed with the VAS scale within four weeks after surgery (all P > 0.05). Carriers of at least one polymorphic OPRM1 rs1799971 allele had a higher risk of constipation in the first four weeks after surgery compared to non-carriers (OR = 4.5, 95% CI = 1.6–12.64, P = 0.004). Carriers of at least one polymorphic OPRM1 rs677830 allele had a higher risk of constipation after third week of tramadol treatment (OR = 3.11, 95% CI = 1.08–8.89, P = 0.035). Furthermore, carriers of two polymorphic MIR23Brs1011784 alleles had a higher risk of nausea after 28 days of tramadol treatment (OR = 7.35, 95% CI = 1.27–42.6, P = 0.026), while heterozygotes for MIR107 rs2296616 allele had a lower risk of nausea after 21 days of tramadol treatment (OR = 0.21, 95% CI = 0.05–0.87, P = 0.031). In carriers of two polymorphic MIR107 rs2296616 alleles, chronic pain was significantly more common than in carriers of two wild-type alleles (P = 0.004). Carriers of at least one polymorphic MIR23B rs1011784 allele experienced more neuropathic pain after adjustment for tramadol dose (OR = 2.85, 95% CI = 1.07–7.59, P = 0.036), while carriers of at least one polymorphic OPRM1 rs677830 allele experienced less neuropathic pain compared to carriers of two wild-type alleles (OR = 0.38, 95% CI = 0.15–0.99, P = 0.047).Conclusions.Genetic variability of OPRM1 and genes coding for miRNAs that could affect OPRM1 expression may be associated with adverse effects of tramadol/paracetamol treatment as well as with chronic and neuropathic pain after breast cancer surgery with axillary lymphadenectomy. Ključne besede: operacija raka na dojki, zdravljenje bolečine, tramadol Objavljeno v DiRROS: 25.07.2024; Ogledov: 18; Prenosov: 7
Celotno besedilo (1,48 MB) Gradivo ima več datotek! Več... |
3. Minimally invasive CT guided treatment of intraspinal synovial cystSergeja Kozar, Miran Jeromel, 2014, izvirni znanstveni članek Povzetek: Background. Intraspinal synovial cysts of vertebral facet joints are uncommon cause of radicular pain as well as neurological deficits. They can be managed both conservatively and surgically.Case report. A 77-year old polymorbid patient presented with bilateral low back pain which worsened during the course of time and did not respond to the conservative treatment. A diagnosis of intraspinal synovial cyst was made using the magnetic resonance imaging (MRI). Percutaneous computed tomography (CT) guided injection with installation of local anesthetic together with corticosteroid and rupture of the cyst was successfully used. A month after the procedure his pain improved, the usage of analgesics diminished and his over-all quality of life improved.Conclusions. Percutaneous CT guided lumbar synovial cyst treatment is safe and reliable alternative to the surgical treatment in polymorbid patients with radiculopathy who are not able to tolerate general anesthesia and operation. Ključne besede: ciste, intraspinalne sinovialne ciste, bolečina, zdravljenje, radiologija Objavljeno v DiRROS: 11.04.2024; Ogledov: 253; Prenosov: 126
Celotno besedilo (515,68 KB) Gradivo ima več datotek! Več... |
4. Electrogene therapy with interleukin-12 in canine mast cell tumorsDarja Pavlin, Maja Čemažar, Andrej Cör, Gregor Serša, Azra Pogačnik, Nataša Tozon, 2011, izvirni znanstveni članek Ključne besede: psi, tumor, zdravljenje, elektrogenska terapija, plazmidi Objavljeno v DiRROS: 19.03.2024; Ogledov: 247; Prenosov: 90
Celotno besedilo (667,74 KB) |
5. Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer : a single institution retrospective analysisMartina Reberšek, Marko Boc, Petra Škerl, Jernej Benedik, Zvezdana Hlebanja, Neva Volk, Srdjan Novaković, Janja Ocvirk, 2011, izvirni znanstveni članek Ključne besede: rak (medicina), debelo črevo, danka, zdravljenje Objavljeno v DiRROS: 18.03.2024; Ogledov: 228; Prenosov: 77
Celotno besedilo (461,04 KB) |
6. Sinonasal inverted papilloma associated with squamous cell carcinomaJasna But-Hadžić, Klemen Jenko, Mario Poljak, Boštjan Kocjan, Nina Gale, Primož Strojan, 2011, izvirni znanstveni članek Ključne besede: rak (medicina), papiloma virusi, nosna votlina, karcinom, zdravljenje, radioterapija Objavljeno v DiRROS: 18.03.2024; Ogledov: 266; Prenosov: 69
Celotno besedilo (513,64 KB) |
7. |
8. Lymphedema following cancer therapy in Slovenia : a frequently overlooked condition?Tanja Planinšek Ručigaj, Nada Kecelj, Vesna Tlaker Žunter, 2010, izvirni znanstveni članek Povzetek: Introduction. Secondary lymphedema following cancer therapy is a frequent, often painful, quality of life disturbing condition, reducing the patients' mobility and predisposing them to complications, e.g. infections and malignancies. The critical aspect of lymphedema therapy is to start as soon aspossible to prevent the irreversible tissue damage. Patients and methods. Weperformed a retrospective study of patients with lymphedema, treated at the Department of Dermatovenereology, University Medical Center Ljubljana, from January 2002 to June 2010. The patientsć demographic and medical data were collected, including type of cancer, type and stage of lymphedema, and time tofirst therapy of lymphedema. The number of referred patients with lymphedema following the therapy of melanoma, breast cancer, and uterine/cervical cancer, was compared to the number of patients expected to experience lymphedema following cancer therapy, calculated from the incidence reported in the literature. Results. In the period of 8.5 years, 543 patients (432 females, 112 males) with lymphedema were treated. The results show that probably many Slovenian patients with secondary lymphedema following cancer therapy remain unrecognized and untreated or undertreated. In the majority of our patients, the management of lymphedema was delayedč on average, the patients first received therapy for lymphedema 3.6 years after the first signsof lymphedema. Conclusions. To avoid a delay in diagnosis and therapy, and the complications of lymphedema following cancer therapy, the physician should actively look for signs or symptoms of lymphedema during the follow-up period, and promptly manage or refer the patients developing problems. Ključne besede: rak (medicina), zdravljenje, limfedem Objavljeno v DiRROS: 18.03.2024; Ogledov: 209; Prenosov: 60
Celotno besedilo (416,52 KB) |
9. Imaging findings in bisphosphonate-induced osteonecrosis of the jawsKatarina Šurlan Popović, Miha Kočar, 2010, izvirni znanstveni članek Ključne besede: rak (medicina), bisfosfonati, radiologija, zdravljenje, čeljustnica, nekroze, diagnostika Objavljeno v DiRROS: 18.03.2024; Ogledov: 259; Prenosov: 68
Celotno besedilo (737,45 KB) |
10. |